Cell-targeted lytic pore-forming agents

Details Cell-targeted lytic pore-forming agents Cell-targeted lytic pore-forming agents

1996-12-05

1998-10-20

Eisenschenk, Frank C.

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

530352, 530395, 530400, 530402, 530825, C07K 14195, C07K 14315, A61K 3816

Patent

active

058247769

ABSTRACT:
A chimeric compound that contains a cell-specific ligand linked to a pore-forming agent capable of lysing a cell.

REFERENCES:
patent: 4867973 (1989-09-01), Goers et al.
patent: 4975278 (1990-12-01), Senter et al.
Higaki, J. et al. Trends in Biochem. Sci. 17: 100-104, 1992.
Corey, D. R. et al. J. Biol. Chem. 264(7): 3666-3669, Mar. 1989.
Amato, "Molecular Design Gets Into a Hole", Science, 255: 684 (1992).
Bayley, "Novel Biomaterials: Genetically Engineered Pores", 1990 Dept. of Energy Grant No. DE-FG02-90R20018, Worcester Foundation for Experimental Biology.
Chovnich et al., "A Recombinant Membrane-acting Immunotoxin", Cancer Res., 51:465-67 (1991).
Ellman et al., "Site-Specific Incorporation of Novel Backbone Structures into Proteins", Science, 255:197-200 (1992).
Gray et al., "Primary Sequence of the .alpha.-Toxin Gene from Staphylococcus Aureus Wood 46", Inf. Immun., 46:615-18 (1984).
Harris et al., "Therapeutic Antibodies-The Coming of Age", Tiblech, 11:4-44 (1993).
Hird et al., "Immunotherapy with Monoclonal Antibodies", Genes & Cancer, Ch. 17: pp. 183-189, (1990).
Huston et al., "Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins", Meth. Enzymol., 203:46-89 (1991).
Maiti et al., "Tolerogenic Conjugates of Xenogeneic Monoclonal Antibodies with Monomethoxypoltethylene Glycol I. Induction of Long-Lasting Tolerance to Xenogenic Antibodies", Int. J. Cancer Suppl. 3:17-22 (1988).
Noren et al., "A General Method of Site-Specific Incorporation of Unnatural Amino Acids into Proteins", Science, 244:182-188 (1989).
Osband et al., "Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy", Immunol. Today, 11:193-95 (1990).
Pastan, et al., "Immunotoxins", Cell, 47:641-48 (1986).
Regen et al., "Supramolecular Surfactants: Amphiphilic Polymers Designed to Disrupt Lipid Membranes", Biochem. biophys. Res. Commun., 159:566-571 (1989).
Stetler-Stevensen et al., "The Activation of Human Type IV Collagenase Proenzyme", J. Biol. Chem., 264:1353-56 (1989).
Thelestam et al., "Staphylococcal Alpha Toxin-Recent Advances", Toxicon, 26:51-65 (1988).
Tobkes et al., "Secondary Structure and Assembly Mechanism of an Oligomeric Channel Protein", Biochemistry, 24:1915-20 (1985).
Walker et al., "Functional Expression of the .alpha.-Hemolysin of Staphylococcus aureus in Intact Escherichia Coli and in Cell Lysates", J. Biol. Chem., 267:10902-909 (1992).
Walker et al. "Assembly of the Oligomeric Membrane Pore Formed by Staphylococal .alpha.-Hemolysin Examined by Truncation Mutagenesis", J. Biol. Chem., 267:21782-86 (1992).
Walker et al., "Functional Complementation of Staphylococcal .alpha.-Hemolysin Fragments", J. Biol. Chem., 268:5285-92, 1993.
Walker et al., "A Pore-forming Protein with a Protease-actuated Trigger", Protein Eng., 7:91-97 (1994).

Affiliated with

Also associated with

Rating

Cell-targeted lytic pore-forming agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cell-targeted lytic pore-forming agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell-targeted lytic pore-forming agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-245333